- 15 Jul 2022
- ICICIdirect Research
Syngene inks biologics manufacturing agreement with ZoetisSYNGENE - 576 Change: 0.80 (0.14 %)
News: Syngene has signed a 10- year agreement with Zoetis, to manufacture the drug substance for Librela (bedinvetmab), a first in class monoclonal antibody used for treating osteoarthritis in dogs. This agreement, initially centred on Librela, paves the way for development and manufacture of other molecules in coming years and is expected to be worth up to US$500 million to Syngene over 10 years.
Views: Syngene’s collaboration with Zoetis started in 2011 with Syngene engaged in development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of a treatment for allergic or atopic dermatitis and Librela. This agreement serves as an inflection point for development and manufacturing services with potential to position Syngene as a leading CDMO in animal health globally. The company will need to complete the regulatory inspections for commercial supplies to Zoetis. Librela is expected to be a blockbuster drug for Zoetis with CY22 guidance of US$100 million from Europe while US approval is also expected later in 2022. We believe this agreement is testament to Syngene’s ability to encapsulate the whole value chain from research to commercial manufacturing for innovators.